Healthcare / BiotechnologyStockholm
$0.20
+0.00 (+0.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 11%
FCF escenarios
weak_data · normalized FCF $-191.7M · quality 23.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$123M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-748.7%
↓Gross Margin
N/A
•Debt/Equity
6.29
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-75.7%
FCF CAGR
—
FCF margin
-30631.5%
FCF / Net income
3.07x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $514000.0 · net income $-51.4M · FCF $-157.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $514000.00 | $514000.00 | $57.8M | $58.1M | $35.7M |
| Net Income | $-51.4M | $-51.4M | $-233.9M | $-248.6M | $-193.4M |
| EBITDA | $-5.1M | $-5.1M | $-169.8M | $-237.6M | $-181.0M |
| EPS | -1.87 | -1.87 | -7.74 | -22.61 | -36.18 |
| Operating Margin | -23669.3% | -23669.3% | -328.4% | -429.2% | -538.7% |
| Net Margin | -9990.3% | -9990.3% | -404.9% | -427.8% | -541.8% |
| Balance Sheet | |||||
| Debt/Equity | 6.29 | 6.29 | -1.38 | 1.40 | 0.28 |
| Current Ratio | 1.76 | 1.76 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-157.4M | $-157.4M | $-221.8M | $-191.7M | $-173.0M |
| Returns | |||||
| ROE | -748.7% | -748.7% | 179.1% | -2096.9% | -217.2% |
| Valuation | |||||
| P/B | 0.79 | 0.79 | — | 63.02 | 6.70 |
| Growth & Yield | |||||
| Revenue Growth | -99.1% | -99.1% | -0.6% | 62.8% | — |
| EPS Growth | 75.8% | 75.8% | 65.8% | 37.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-95.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-7.74 → -1.87
Residual
-95.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.